23/07/2026 Phase 3 MonumenTAL-6 study shows PFS benefit for TECVAYLI + TALVEY combo in Multiple Myeloma Epcoritamab Phase 3 DLBCL trial failed to meet OS endpoint Phase 3 MonumenTAL-6 study shows PFS benefit for TECVAYLI + TALVEY combo in Multiple Myeloma (Ref) Johnson & Johnson announced positive topline results from the Phase 3 MonumenTAL-6 trial of TECVAYLI and TALVEY combinations in relapsed/refractory multiple myeloma patients. MonumenTAL-6 trial evaluated TECVAYLI® (tec

March 1st Week, 2026 Regulatory Events 🎯 The European Commission approved Incyte’s retifanlimab (anti-PD-1) + carboplatin + paclitaxel for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal. (Ref 1) ❓ How do the outcomes of this regimen compare against the current SOC? 🎯 The US FDA approved Johnson & Johnson Innovative Medicine’s teclistamab (BCMA-directed CD3 T-cell engager) + daratumuma

15/12/2025 Daiichi Sankyo and AstraZeneca's trastuzumab deruxtecan + pertuzumab has been approved for first-line HER2+ve breast cancer FibroGen's roxadustat received the FDA Orphan Drug Designation for myelodysplastic syndromes Eli Lilly's TECVAYLI plus DARZALEX FASPRO combo has been selected for the FDA's CNPV Pilot program Daiichi Sankyo and AstraZeneca's trastuzumab deruxtecan + pertuzumab has been approved for first-line HER2+ve breast cancer (Ref) The US FDA granted appr